Cumberland Pharmaceuticals sells FDA-approved brands for $100M, focusing on orphan drug development.

Cumberland Pharmaceuticals announced a $100 million strategic transaction with Apotex Inc., selling its portfolio of FDA-approved brands to focus on developing orphan drug candidates addressing unmet medical needs. The deal, pending shareholder approval, aims to unlock shareholder value and support Cumberland's transition to a development-stage biopharmaceutical company. Cumberland's pipeline includes promising clinical programs for ifetroban, targeting rare diseases like Duchenne muscular dystrophy, systemic sclerosis, and pulmonary fibrosis, with recent FDA Fast Track designation for DMD. The company reported $9.1 million in Q1 2026 revenue and a net loss of $3.3 million, reflecting its shift towards innovation and development.